Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT

L. Ruggeri, L. Vago, DJ. Eikema, LC. de Wreede, F. Ciceri, MA. Diaz, F. Locatelli, P. Jindra, G. Milone, JL. Diez-Martin, JA. Pérez-Simón, M. Merluzzi, L. Koster, S. van der Werf, A. van Biezen, A. Toubert, A. Nagler, C. Chabannon, C. Bonini, A. Velardi

. 2021 ; 56 (8) : 1900-1907. [pub] 20210325

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22003978
E-resources Online Full text

NLK Free Medical Journals from 1997 to 1 year ago
Freely Accessible Science Journals from 1997 to 1 year ago
ProQuest Central from 2000-01-01 to 1 year ago
Open Access Digital Library from 1997-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 1 year ago

Links

PubMed 33767404
DOI 10.1038/s41409-021-01259-0
Knihovny.cz E-resources

Human leukocyte antigen (HLA) class-I mismatches that trigger donor-versus-recipient natural killer (NK)-cell alloreactivity reduce the incidence of leukemia relapse and improve survival of acute myeloid leukemia patients after T-cell-depleted HLA-haplotype mismatched ("haploidentical") hematopoietic transplantation. In murine graft-versus-host disease (GvHD) models, alloreactive NK-cells also prevent GvHD. Here we report the results of a non-interventional, prospective study performed on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. The study was aimed at re-assessing the role of NK-cell alloreactivity in a cohort of haploidentical transplants performed in Europe between 2012 and 2015 and composed of unmanipulated, as well as T-cell-depleted transplants. One hundred thirty-eight patients with acute myeloid or lymphoid leukemias were analyzed. Eighty-six patients received ex-vivo T-cell-depleted transplants, 52 patients received unmanipulated transplants. Fifty patients were transplanted from NK alloreactive donors, 88 from non-NK alloreactive donors. NK cell alloreactivity did not impact on GvHD/relapse-free survival (GRFS) in unmanipulated transplants (HR: 1.66 (0.9-3.1), p = 0.1). In contrast, it did impact beneficially on GRFS in T-cell-depleted transplants (HR: 0.6, (0.3-1.2), p = 0.14, interaction p < 0.001). This effect was the consequence of reduced incidences of acute and chronic GvHD and non-relapse mortality.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003978
003      
CZ-PrNML
005      
20220127145654.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-021-01259-0 $2 doi
035    __
$a (PubMed)33767404
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ruggeri, Loredana $u University of Perugia, Perugia, Italy. loredana.ruggeri@ospedale.perugia.it
245    10
$a Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT / $c L. Ruggeri, L. Vago, DJ. Eikema, LC. de Wreede, F. Ciceri, MA. Diaz, F. Locatelli, P. Jindra, G. Milone, JL. Diez-Martin, JA. Pérez-Simón, M. Merluzzi, L. Koster, S. van der Werf, A. van Biezen, A. Toubert, A. Nagler, C. Chabannon, C. Bonini, A. Velardi
520    9_
$a Human leukocyte antigen (HLA) class-I mismatches that trigger donor-versus-recipient natural killer (NK)-cell alloreactivity reduce the incidence of leukemia relapse and improve survival of acute myeloid leukemia patients after T-cell-depleted HLA-haplotype mismatched ("haploidentical") hematopoietic transplantation. In murine graft-versus-host disease (GvHD) models, alloreactive NK-cells also prevent GvHD. Here we report the results of a non-interventional, prospective study performed on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. The study was aimed at re-assessing the role of NK-cell alloreactivity in a cohort of haploidentical transplants performed in Europe between 2012 and 2015 and composed of unmanipulated, as well as T-cell-depleted transplants. One hundred thirty-eight patients with acute myeloid or lymphoid leukemias were analyzed. Eighty-six patients received ex-vivo T-cell-depleted transplants, 52 patients received unmanipulated transplants. Fifty patients were transplanted from NK alloreactive donors, 88 from non-NK alloreactive donors. NK cell alloreactivity did not impact on GvHD/relapse-free survival (GRFS) in unmanipulated transplants (HR: 1.66 (0.9-3.1), p = 0.1). In contrast, it did impact beneficially on GRFS in T-cell-depleted transplants (HR: 0.6, (0.3-1.2), p = 0.14, interaction p < 0.001). This effect was the consequence of reduced incidences of acute and chronic GvHD and non-relapse mortality.
650    _2
$a zvířata $7 D000818
650    12
$a nemoc štěpu proti hostiteli $x prevence a kontrola $7 D006086
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a buňky NK $7 D007694
650    12
$a akutní myeloidní leukemie $x terapie $7 D015470
650    _2
$a myši $7 D051379
650    _2
$a prospektivní studie $7 D011446
650    _2
$a haploidentická transplantace $7 D000075442
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vago, Luca $u Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy
700    1_
$a Eikema, Diderik-Jan $u EBMT Statistical Unit, Leiden, The Netherlands
700    1_
$a de Wreede, Liesbeth C $u Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Ciceri, Fabio $u Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy
700    1_
$a Diaz, Miguel Angel $u Niño Jesus Children's Hospital, Madrid, Spain
700    1_
$a Locatelli, Franco $u IRRCS Ospedale Pediatrico Bambino Gesů, Rome, Italy
700    1_
$a Jindra, Pavel $u Charles University Hospital, Pilsen, Czech Republic
700    1_
$a Milone, Giuseppe $u Ospedale Ferrarotto, Catania, Italy
700    1_
$a Diez-Martin, Josè Luis $u Hospital Gregorio Marañón, Madrid, Spain
700    1_
$a Pérez-Simón, Jose Antonio $u Hospital Universitario Virgen del Rocío, Sevilla, Spain
700    1_
$a Merluzzi, Mara $u University of Perugia, Perugia, Italy
700    1_
$a Koster, Linda $u EBMT Data Office Leiden, Leiden, The Netherlands
700    1_
$a van der Werf, Steffie $u EBMT Data Office Leiden, Leiden, The Netherlands
700    1_
$a van Biezen, Anja $u EBMT Data Office Leiden, Leiden, The Netherlands
700    1_
$a Toubert, Antoine $u Hôpital Saint-Louis, APHP, INSERM U1160, Université Paris Diderot, Paris, France
700    1_
$a Nagler, Arnon $u Chaim Sheba Medical Center, Tel-Hashomer, Israel
700    1_
$a Chabannon, Christian $u Institut Paoli-Calmettes, Centre de Lutte Contre le Cancer; Centre d'Investigations Cliniques en Biothérapie, Université d'Aix-Marseille, Inserm CBT, Marseille, France
700    1_
$a Bonini, Chiara $u Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milano, Italy
700    1_
$a Velardi, Andrea $u University of Perugia, Perugia, Italy
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 56, č. 8 (2021), s. 1900-1907
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33767404 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145650 $b ABA008
999    __
$a ok $b bmc $g 1751438 $s 1155127
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 56 $c 8 $d 1900-1907 $e 20210325 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20220113
Back

Find record

Citation metrics

Archiving options